Systemic therapy for hepatocellular Carcinoma and cholangiocarcinoma

Surgical Oncology Clinics of North America

Volumn 24, Issue 1, 2015, Pages 187-198

  Chung, Vincent ^a  

^a City of Hope ^*  (United States)

Author keywords

Chemotherapy; Cholangiocarcinoma; Hepatocellular carcinoma; Molecular targets

Indexed keywords

ANTIHYPERTENSIVE AGENT; ARGINASE 1; BEVACIZUMAB; BRIVANIB; CABOZANTINIB; CAPECITABINE; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; FORETINIB; GEMCITABINE; LINIFANIB; LOPERAMIDE; MIPSAGARGIN; MITOGEN ACTIVATED PROTEIN KINASE; OXALIPLATIN; PLACEBO; PLATELET DERIVED GROWTH FACTOR; RAF PROTEIN; RAS PROTEIN; REGORAFENIB; SORAFENIB; SUNITINIB; TIVANTINIB; TRAMETINIB; UNINDEXED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT;

BILE DUCT CARCINOMA; BONE MARROW SUPPRESSION; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CARDIOMYOPATHY; CELL PROLIFERATION; CHEMOEMBOLIZATION; CHILD PUGH SCORE; DIARRHEA; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TARGETING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HAND FOOT SYNDROME; HEART INJURY; HUMAN; HYPERTENSION; LETHARGY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PATIENT SELECTION; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTON THERAPY; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIGNAL TRANSDUCTION; STEREOTACTIC BODY RADIATION THERAPY; UNSPECIFIED SIDE EFFECT; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; DRUG EFFECTS; INTRAHEPATIC BILE DUCT; LIVER NEOPLASMS; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; HUMANS; LIVER NEOPLASMS;

EID: 84922837768     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2014.09.009     Document Type: Review

References (24)

1. American Cancer Society Cancer facts & figures 2014 2014, American Cancer Society, Atlanta(GA).
2. White D.L., Kanwal F., El-Serag H.B. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 2012, 10(12):1342-1359.e2.
3. Llovet J.M., Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008, 48(4):1312-1327.
4. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. NEngl J Med 2008, 359(4):378-390.
5. Mir O., Coriat R., Boudou-Rouquette P., et al. Sorafenib-induced diarrhea and hypophosphatemia: mechanisms and therapeutic implications. Ann Oncol 2012, 23(1):280-281.
6. Maitland M.L., Kasza K.E., Karrison T., et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res 2009, 15(19):6250-6257.
7. Mazzaferro V., Bhoori S., Sposito C., et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl 2011, 17(Suppl 2):S44-S57.
8. Lim K.C., Chow P.K., Allen J.C., et al. Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria. Br J Surg 2012, 99(12):1622-1629.
9. Cheng A.L., Kang Y.K., Lin D.Y., et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. JClin Oncol 2013, 31(32):4067-4075.
10. Johnson P.J., Qin S., Park J.W., et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. JClin Oncol 2013, 31(28):3517-3524.
11. Cheng A.L., Kang Y.K., Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10(1):25-34.
12. Cainap C., Qin S., Huang W.-T., et al. Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC). JClin Oncol 2013, 30(suppl 34). [abstract 249].
13. Zhu A, Rosmorduc O, Evans J, etal. Search: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with hepatocellular carcinoma (HCC). ESMO, [abstract 917].
14. Tetef M., Doroshow J., Akman S., et al. 5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial. Cancer Invest 1995, 13(5):460-463.
15. Qin S., Bai Y., Lim H.Y., et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. JClin Oncol 2013, 31(28):3501-3508.
16. Doroshow J.H., Synold T.W., Gandara D., et al. Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group. Semin Oncol 2003, 30(4 Suppl 15):14-19.
17. Valle J.W., Wasan H., Johnson P., et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study. Br J Cancer 2009, 101(4):621-627.
18. Valle J., Wasan H., Palmer D.H., et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. NEngl J Med 2010, 362(14):1273-1281.
19. Knox J.J., Hedley D., Oza A., et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. JClin Oncol 2005, 23(10):2332-2338.
20. Andre T., Reyes-Vidal J.M., Fartoux L., et al. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer 2008, 99(6):862-867.
21. Philip P.A., Mahoney M.R., Allmer C., et al. Phase II study of erlotinib in patients with advanced biliary cancer. JClin Oncol 2006, 24(19):3069-3074.
22. Lee J., Park S.H., Chang H.M., et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2012, 13(2):181-188.
23. Socoteanu M.P., Mott F., Alpini G., et al. c-Met targeted therapy of cholangiocarcinoma. World J Gastroenterol 2008, 14(19):2990-2994.
24. Nakazawa K., Dobashi Y., Suzuki S., et al. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. JPathol 2005, 206(3):356-365.